Annual report [Section 13 and 15(d), not S-K Item 405]

SCHEDULE OF SEGMENT INFORMATION (Details)

SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2025	Oct. 31, 2024
Segment Reporting Information [Line Items]
Revenues
Research & development expenses	5,071	6,396
General & administrative expenses	6,630	7,435
Total operating costs and expenses	11,701	13,831
Loss from operations	(11,701)	(13,831)
Interest income	673	1,133
Net loss	(11,028)	(12,698)
Total operating expenses	11,701	13,831
Less non-cash stock-based compensation	(3,810)	(4,782)
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure)	7,891	9,049
Total assets	16,080	21,591
Cancer Vaccines [Member]
Segment Reporting Information [Line Items]
Revenues
Research & development expenses	3,121	3,748
General & administrative expenses	4,137	4,291
Total operating costs and expenses	7,258	8,039
Loss from operations	(7,394)	(8,039)
Interest income	417	651
Net loss	(6,841)	(7,388)
Total operating expenses	7,258	8,039
Less non-cash stock-based compensation	(2,365)	(2,804)
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure)	4,893	5,235
Total assets	9,604	12,917
CAR-T Therapeutics [Member]
Segment Reporting Information [Line Items]
Revenues
Research & development expenses	1,950	2,648
General & administrative expenses	2,439	3,084
Total operating costs and expenses	4,389	5,732
Loss from operations	(4,453)	(5,732)
Interest income	252	476
Net loss	(4,137)	(5,256)
Total operating expenses	4,389	5,732
Less non-cash stock-based compensation	(1,435)	(1,966)
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure)	2,954	3,766
Total assets	6,347	8,535
Other [Member]
Segment Reporting Information [Line Items]
Revenues
Research & development expenses
General & administrative expenses	54	60
Total operating costs and expenses	54	60
Loss from operations	(54)	(60)
Interest income	4	6
Net loss	(50)	(54)
Total operating expenses	54	60
Less non-cash stock-based compensation	(10)	(12)
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure)	44	48
Total assets	$ 129	$ 139